Augment Investments has announced its acquirement of an additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the completion of the transaction.
Augment Investments has announced to acquire additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the completion of the transaction.
According to the transaction, Augment will hold 15.2m global depository receipts (GDS) of Pharmstandard.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact
Excellence in Action Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..
